Treatment of Early Supraglottic Squamous Cell Carcinoma With Advance Technologies

Launched by CENTRE HOSPITALIER UNIVERSITAIRE UCLOUVAIN NAMUR · Nov 3, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at different treatment options for early-stage supraglottic squamous cell carcinoma, which is a type of throat cancer. Researchers want to compare three treatments: radiotherapy with or without chemotherapy, trans-oral laser microsurgery (TLM), and trans-oral robotic surgery (TORS). The main goal is to see how effective each treatment is by looking at various factors, including patients' quality of life before and after treatment, the outcomes related to the cancer, how well patients can function, and the costs associated with each treatment.

To participate in this trial, you must be at least 18 years old and have a confirmed diagnosis of early-stage supraglottic squamous cell carcinoma. You should also be in good enough health to give informed consent and participate in the study. Some reasons you might not be eligible include having had previous treatments for head and neck cancer or other serious medical conditions. If you join, you can expect to complete questionnaires about your quality of life and undergo different treatments while being monitored by a team of medical professionals. This trial is currently recruiting participants, and it aims to enroll a total of 108 patients across the three treatment groups.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of SSCC (with histological confirmation)
• • cT1-T2 / cN0-N1/ M0 according to 8th TNM classification (UICC/AJCC)
• • WITH a Multidisciplinary Tumor Board decision according to the NCCN or European guidelines
• • Diagnostic imaging (Head and neck and pulmonary CT or PET/CT, +/- IRM if needed) realized within 1 month before the study inclusion
• • ≥ 18 years old and able to provide an informed consent
• • ECOG/WHO performance status ≤ 2
• Exclusion Criteria:
• • - Previous radiotherapy +/- chemotherapy treatment of the head and neck region
• • Previous history of head and neck cancer within 5 years
• • Prior invasive malignant disease unless disease-free for at least 5 years or more, with exception of non-melanoma skin cancer
• • Non-supraglottic or unknown primary site
• • Clinical and radiological signs of nodal extracapsular extension
• • Significant trismus (maximum inter-incisal opening ≤ 35 mm)
• • Pre-existing dysphagia not related to the cancer or the biopsy (from neurological disorders for example)
• • Unable or unwilling to complete Quality of Life questionnaires
• • Serious medical comorbidities or contraindication for surgery and/or radiation
• • Pregnancy and lactation